ESMO Open最新文献

{"title":"18P PIK3CA mutations in relapse risk stratification of stage I endometrial cancers with no special molecular profile","authors":"C. De Angelis , C. Bartoli , F. Scolari , E. Pieroni , F. Castiglione , M.C. Petrella , F. Sorbi , M. Fambrini , S. Pillozzi , L. Antonuzzo","doi":"10.1016/j.esmoop.2024.103518","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103518","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012870/pdfft?md5=38e8d17d97634edc868814d4783fe3f2&pid=1-s2.0-S2059702924012870-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"22O Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study","authors":"C. Le Tourneau , C.I. Rojas , A. Leary , K. Yonemori , I. Lugowska , D. Tosi , F. Ghiringhelli , C. Caglevic , E.P. Yanez Ruiz , R. Perets , S.Y. Rha , P. Salman , T. Doi , Y. Zhang , G. Akturk , C.E. Pena , T. Keenan , Y. Chen , E. Dettman , O. Ozyilkan","doi":"10.1016/j.esmoop.2024.103522","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103522","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012912/pdfft?md5=b28512bdc4047aeb09946fde3f2795a7&pid=1-s2.0-S2059702924012912-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"27P Concurrent chemoradiotherapy and immunotherapy for locally advanced cervical cancer: A cost-effectiveness analysis based on the KEYNOTE-A18 trial","authors":"K. Liu, Y. Zhu, H. Zhu","doi":"10.1016/j.esmoop.2024.103527","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103527","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012961/pdfft?md5=15e505d58987d9ff9b312f13a16c9d17&pid=1-s2.0-S2059702924012961-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"25P Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study","authors":"K. Yonemori , C.I. Rojas , A. Leary , C. Le Tourneau , I. Lugowska , O. Ozyilkan , C. Caglevic , F. Ghiringhelli , E.P. Yanez Ruiz , M.V. Dongen , R. Perets , M. Gumus , M. Kwiatkowski , S.Y. Rha , P. Salman , Q. Liu , T. Keenan , A.M. Nguyen , P. Singhal , D. Tosi","doi":"10.1016/j.esmoop.2024.103525","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103525","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012948/pdfft?md5=223867c762a3864522d09229c7967d40&pid=1-s2.0-S2059702924012948-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O","authors":"F. Trillsch , A. Okamoto , J-W. Kim , A. Reuss , M.J. Rubio Pérez , M.A. Vardar , V. Salutari , J-S. Frenel , H. Kärkkäinen , N. Colombo , A.M. Chudecka-Glaz , P. Oppelt , S. Lheureux , C. Lamot , T. Engler , R.M. Wenham , S. Nishio , A. Correa , P. Harter , C. Aghajanian","doi":"10.1016/j.esmoop.2024.103550","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103550","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S205970292401319X/pdfft?md5=fad8b5efea191ce61c47adaee10d590c&pid=1-s2.0-S205970292401319X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors","authors":"M.A. Gouda ,&nbsp;J. Shunyakova ,&nbsp;A. Naing ,&nbsp;E. Dumbrava ,&nbsp;D.S. Hong ,&nbsp;Y. Yuan ,&nbsp;P. Yang ,&nbsp;A. Myers ,&nbsp;Y. Liang ,&nbsp;J. Peng ,&nbsp;D. Karp ,&nbsp;A.M. Tsimberidou ,&nbsp;J. Rodon ,&nbsp;T.A. Yap ,&nbsp;S.A. Piha-Paul ,&nbsp;F. Meric-Bernstam ,&nbsp;S. Fu","doi":"10.1016/j.esmoop.2024.103486","DOIUrl":"10.1016/j.esmoop.2024.103486","url":null,"abstract":"<div><h3>Background</h3><p>Paclitaxel resistance limits durability of response in patients with initial clinical benefit. Overexpression of spleen tyrosine kinase (SYK) has been proposed as a possible resistance mechanism. This phase I trial evaluated the safety and preliminary activity of the SYK inhibitor TAK-659 combined with paclitaxel in patients with advanced taxane-refractory solid tumors.</p></div><div><h3>Patients and methods</h3><p>Patients with advanced solid tumors and prior progression on taxane-based therapy received intravenous infusion of paclitaxel on days 1, 8, and 15 plus oral TAK-659 daily in 28-day cycles. The dose-escalation phase included six cohorts treated at different dose levels; the dose-expansion phase included patients with ovarian cancer treated at the highest dose level. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Efficacy was evaluated using Response Evaluation Criteria in Solid Tumors version 1.1.</p></div><div><h3>Results</h3><p>Our study included 49 patients. Maximum tolerated dose was not reached, but higher rates of adverse events were observed at higher dose levels. There were no treatment-related deaths. The most common treatment-related adverse events of any grade were increased aspartate aminotransferase (<em>n</em> = 31; 63%), increased alanine aminotransferase (<em>n</em> = 26; 53%), decreased neutrophil count (<em>n</em> = 26; 53%), and decreased white blood cell count (<em>n</em> = 26; 53%). Most adverse events were either grade 1 or 2. In the 44 patients with evaluable disease, 12 (27%) had stable disease as the best overall response, including three patients with prolonged stable disease, and 4 patients (9%) achieved a partial response.</p></div><div><h3>Conclusions</h3><p>The combination of paclitaxel and TAK-659 showed preliminary activity possibly overcoming resistance to taxane-based therapy as well as a tolerable safety profile in patients with advanced solid tumors.</p></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012559/pdfft?md5=e6c1a0a4356eb28803380a9a2f802530&pid=1-s2.0-S2059702924012559-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141394807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"20P Unexpected germline pathogenic variants in gynaecologic cancers identified through a comprehensive cancer genome profiling programme","authors":"S. Duranti ,&nbsp;A. Panfili ,&nbsp;C. Nero ,&nbsp;A. Minucci ,&nbsp;A. Pietrosante ,&nbsp;J. Preziosi ,&nbsp;I. Marino ,&nbsp;F. Giacomini ,&nbsp;T. Pasciuto ,&nbsp;I. Mozzetta ,&nbsp;L. Giacò ,&nbsp;V. Iacobelli ,&nbsp;A. Preziosi ,&nbsp;A. Piermattei ,&nbsp;G. Maneri ,&nbsp;A. Fagotti ,&nbsp;F. Fanfani ,&nbsp;E. Lucci Cordisco ,&nbsp;M. Genuardi ,&nbsp;G. Scambia","doi":"10.1016/j.esmoop.2024.103520","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103520","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012894/pdfft?md5=7c2ed47519ce0ce271d996c301425523&pid=1-s2.0-S2059702924012894-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"23O A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia","authors":"Y. Xiang ,&nbsp;K. Hasegawa ,&nbsp;H. Zhu ,&nbsp;Q. Zhou ,&nbsp;X. Zhang ,&nbsp;J-Y. Lee ,&nbsp;T. Usami ,&nbsp;W. Zhao ,&nbsp;E. Tharavichitkul ,&nbsp;S. Suzuki ,&nbsp;T-C. Chang ,&nbsp;G.N. Zhang ,&nbsp;C-L. Chang ,&nbsp;A-A. Lertkhachonsuk ,&nbsp;B-G. Kim ,&nbsp;K. Li ,&nbsp;K.U. Yamada ,&nbsp;S. Toker ,&nbsp;D. Lorusso","doi":"10.1016/j.esmoop.2024.103523","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103523","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924012924/pdfft?md5=c2e007b99e4d946ef11c3e74303871d6&pid=1-s2.0-S2059702924012924-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"40MO First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status","authors":"E. Van Nieuwenhuysen ,&nbsp;H.S. Chon ,&nbsp;J. Thomes Pepin ,&nbsp;M. Sundborg ,&nbsp;M. Gold ,&nbsp;B-G. Kim ,&nbsp;S.V. Blank ,&nbsp;J. Liu ,&nbsp;M. McCollum ,&nbsp;M. Mori ,&nbsp;K.N. Moore ,&nbsp;C. Joseph de Pádua ,&nbsp;J. Martinez-Garcia ,&nbsp;C. Papadimitriou ,&nbsp;K. Grisan ,&nbsp;R.L. Póka ,&nbsp;C. Donnelly ,&nbsp;X. Liu ,&nbsp;S. Westin","doi":"10.1016/j.esmoop.2024.103540","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103540","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924013097/pdfft?md5=2a0e1522221226c4a46f3fde946c1363&pid=1-s2.0-S2059702924013097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"67P Factors that may influence physicians’ perceptions of “cure” in ovarian cancer: A discrete choice experiment","authors":"R.L. Coleman ,&nbsp;Z. Segunmaru ,&nbsp;D. Simmons ,&nbsp;E.A. Szamreta ,&nbsp;K. Krupsky ,&nbsp;K. Beusterien ,&nbsp;J. Cambron-Mellott ,&nbsp;M.F. Barry ,&nbsp;N. Kashine ,&nbsp;E. Mulvihill","doi":"10.1016/j.esmoop.2024.103574","DOIUrl":"https://doi.org/10.1016/j.esmoop.2024.103574","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2059702924013437/pdfft?md5=51292f208b27021bccebe2a289363137&pid=1-s2.0-S2059702924013437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}